Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
Phase 4
- Conditions
- Heart Failure
- Registration Number
- NCT00418119
- Lead Sponsor
- Rabin Medical Center
- Brief Summary
Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Ischemic heart disease
- Systolic lv dysfunction
- Mild anemia
- Normal renal function
- Stable condition
Exclusion Criteria
- Pregnancy
- Unstable condition
- Under 18 years old
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does erythropoietin modulate in systolic heart failure with anemia and normal renal function?
How does erythropoietin compare to iron supplementation in treating anemic heart failure patients with preserved renal function?
Which biomarkers predict response to erythropoietin therapy in systolic dysfunction with mild anemia?
What are the cardiovascular risks of erythropoietin in heart failure patients with normal renal function?
How do HIF-PH inhibitors compare to erythropoietin for anemia management in systolic heart failure?
Trial Locations
- Locations (1)
Cardiology Department, Rabin Medical Center
🇮🇱Petah Tikva, Israel